Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label

The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.